Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a hold rating to a buy rating in a research report released on Monday.

A number of other research firms have also commented on REGN. Redburn Atlantic upgraded shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, August 14th. Scotiabank assumed coverage on Regeneron Pharmaceuticals in a report on Thursday, November 13th. They issued a “sector perform” rating and a $650.00 target price on the stock. BMO Capital Markets increased their price target on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an “outperform” rating in a research report on Monday, August 4th. Cantor Fitzgerald lifted their price objective on Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a research report on Wednesday, October 29th. Finally, Royal Bank Of Canada increased their target price on Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a report on Wednesday, October 29th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $772.76.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN opened at $702.75 on Monday. Regeneron Pharmaceuticals has a 12 month low of $476.49 and a 12 month high of $800.99. The business’s 50 day moving average is $608.00 and its two-hundred day moving average is $573.41. The company has a market cap of $73.86 billion, a P/E ratio of 16.83, a P/E/G ratio of 2.03 and a beta of 0.31. The company has a quick ratio of 3.72, a current ratio of 4.06 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, beating the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm had revenue of $3.75 billion during the quarter, compared to analysts’ expectations of $3.57 billion. During the same quarter in the prior year, the firm posted $12.46 EPS. The company’s revenue for the quarter was up .9% on a year-over-year basis. On average, equities analysts expect that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Thursday, November 20th will be issued a $0.88 dividend. The ex-dividend date is Thursday, November 20th. This represents a $3.52 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.43%.

Insider Activity

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of the business’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the sale, the vice president directly owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. The trade was a 9.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Christine A. Poon sold 6,500 shares of the firm’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the transaction, the director directly owned 2,352 shares in the company, valued at $1,538,843.04. This trade represents a 73.43% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 7.02% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Captrust Financial Advisors raised its position in shares of Regeneron Pharmaceuticals by 34.4% during the 3rd quarter. Captrust Financial Advisors now owns 14,417 shares of the biopharmaceutical company’s stock valued at $8,106,000 after acquiring an additional 3,694 shares during the last quarter. Coldstream Capital Management Inc. boosted its position in shares of Regeneron Pharmaceuticals by 85.3% in the 3rd quarter. Coldstream Capital Management Inc. now owns 2,027 shares of the biopharmaceutical company’s stock worth $1,140,000 after purchasing an additional 933 shares during the last quarter. Danske Bank A S acquired a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth $31,221,000. Caitong International Asset Management Co. Ltd increased its holdings in Regeneron Pharmaceuticals by 638.9% in the third quarter. Caitong International Asset Management Co. Ltd now owns 968 shares of the biopharmaceutical company’s stock valued at $544,000 after purchasing an additional 837 shares during the last quarter. Finally, Integrated Investment Consultants LLC lifted its stake in Regeneron Pharmaceuticals by 10.5% in the third quarter. Integrated Investment Consultants LLC now owns 756 shares of the biopharmaceutical company’s stock valued at $425,000 after buying an additional 72 shares during the period. 83.31% of the stock is owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.